BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 19913252)

  • 1. Men presenting for radical prostatectomy on preoperative statin therapy have reduced serum prostate specific antigen.
    Krane LS; Kaul SA; Stricker HJ; Peabody JO; Menon M; Agarwal PK
    J Urol; 2010 Jan; 183(1):118-24. PubMed ID: 19913252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative statin therapy is not associated with biochemical recurrence after radical prostatectomy: our experience and meta-analysis.
    Mass AY; Agalliu I; Laze J; Lepor H
    J Urol; 2012 Sep; 188(3):786-91. PubMed ID: 22818136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of statins and prostate cancer recurrence among patients treated with radical prostatectomy.
    Chao C; Jacobsen SJ; Xu L; Wallner LP; Porter KR; Williams SG
    BJU Int; 2013 May; 111(6):954-62. PubMed ID: 23464862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of statin use on clinicopathological characteristics of localized prostate cancer and outcomes obtained after radical prostatectomy: a single center study.
    Cattarino S; Seisen T; Drouin SJ; Renard-Penna R; Leon P; Comperat E; Mozer P; Cussenot O; Rouprêt M
    Can J Urol; 2015 Apr; 22(2):7703-8. PubMed ID: 25891333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of statins to clinical presentation and biochemical outcomes after radical prostatectomy in Korean patients.
    Ku JH; Jeong CW; Park YH; Cho MC; Kwak C; Kim HH
    Prostate Cancer Prostatic Dis; 2011 Mar; 14(1):63-8. PubMed ID: 20938462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of statin use on biochemical outcome following radical prostatectomy.
    Ritch CR; Hruby G; Badani KK; Benson MC; McKiernan JM
    BJU Int; 2011 Oct; 108(8 Pt 2):E211-6. PubMed ID: 21453350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative Statin Use Associated With Lower PSA But Similar Prostate Size and Histopathologic Outcomes: Implications for Active Surveillance?
    Stensland K; McBride RB; Leapman M; Hobbs A; Jazayeri SB; Samadi DB
    Urol J; 2017 May; 14(3):3064-3070. PubMed ID: 28537044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
    Makarov DV; Humphreys EB; Mangold LA; Walsh PC; Partin AW; Epstein JI; Freedland SJ
    J Urol; 2006 Aug; 176(2):554-8. PubMed ID: 16813888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term oncological outcomes of men undergoing radical prostatectomy with preoperative prostate-specific antigen <2.5 ng/ml and 2.5-4 ng/ml.
    Qi P; Tsivian M; Abern MR; Bañez LL; Tang P; Moul JW; Polascik TJ
    Urol Oncol; 2013 Nov; 31(8):1527-32. PubMed ID: 22795501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative Statin Use at the Time of Radical Prostatectomy Is Not Associated With Biochemical Recurrence or Pathologic Upgrading.
    Lyon TD; Turner RM; Yabes JG; Woldemichael E; Davies BJ; Jacobs BL; Nelson JB
    Urology; 2016 Nov; 97():153-159. PubMed ID: 27516122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Is statin use associated with D'Amico risk groups and biochemical recurrence after radical prostatectomy?].
    Misrai V; Do C; Lhez JM; Elman B; Latorzeff I; Portalez D; Grosclaude P
    Prog Urol; 2012 May; 22(5):273-8. PubMed ID: 22515923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statin use and risk of disease recurrence and death after radical prostatectomy.
    Keskiväli T; Kujala P; Visakorpi T; Tammela TL; Murtola TJ
    Prostate; 2016 Apr; 76(5):469-78. PubMed ID: 26689439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
    J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy?
    Loeb S; Yu X; Nadler RB; Roehl KA; Han M; Hawkins SA; Catalona WJ
    J Urol; 2007 Jan; 177(1):102-6; discussion 106. PubMed ID: 17162013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between statins and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy.
    Bañez LL; Klink JC; Jayachandran J; Lark AL; Gerber L; Hamilton RJ; Masko EM; Vollmer RT; Freedland SJ
    Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):722-8. PubMed ID: 20160265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statin use after radical prostatectomy reduces biochemical recurrence in men with prostate cancer.
    Song C; Park S; Park J; Shim M; Kim A; Jeong IG; Hong JH; Kim CS; Ahn H
    Prostate; 2015 Feb; 75(2):211-7. PubMed ID: 25327522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
    Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
    Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
    Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
    J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
    Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
    J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.